Release Date: 29/08/14 12:05 Summary: App 4E / Annual Report to shareholders Price Sensitive: Yes Download Document 5.09MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%